Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Advanced Solid Tumor|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small-cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma
Interventions: GENETIC: Allogeneic natural killer (NK) cell
Sponsor: Fate Therapeutics